PDS Biotech to Acquire Versant Pharmaceuticals
Ticker: PDSB · Form: 8-K · Filed: Mar 13, 2024 · CIK: 1472091
| Field | Detail |
|---|---|
| Company | Pds Biotechnology Corp (PDSB) |
| Form Type | 8-K |
| Filed Date | Mar 13, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00033 |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, merger, pipeline-expansion
TL;DR
PDS Biotech buying Versant Pharma to boost its pipeline. Deal expected Q2 2024.
AI Summary
PDS Biotechnology Corporation announced on March 13, 2024, that it has entered into a definitive agreement to acquire Versant Pharmaceuticals, Inc. The acquisition is expected to close in the second quarter of 2024, subject to customary closing conditions. This move aims to expand PDS Biotech's pipeline and therapeutic capabilities.
Why It Matters
This acquisition could significantly expand PDS Biotechnology's drug development pipeline and enhance its position in the biopharmaceutical market.
Risk Assessment
Risk Level: medium — Acquisitions carry inherent risks, including integration challenges, potential overpayment, and the possibility of not realizing expected synergies.
Key Players & Entities
- PDS Biotechnology Corporation (company) — Registrant
- Versant Pharmaceuticals, Inc. (company) — Target company for acquisition
- March 13, 2024 (date) — Date of report and announcement
- second quarter of 2024 (date) — Expected closing period for the acquisition
FAQ
What is the primary purpose of this Form 8-K filing?
This Form 8-K is filed to report on other events, specifically the definitive agreement for PDS Biotechnology Corporation to acquire Versant Pharmaceuticals, Inc.
When is the acquisition of Versant Pharmaceuticals expected to be completed?
The acquisition is expected to close in the second quarter of 2024.
What are the conditions for the acquisition to close?
The acquisition is subject to customary closing conditions.
What is the former name of PDS Biotechnology Corporation?
The former name of PDS Biotechnology Corporation was Edge Therapeutics, Inc., with a date of name change on September 11, 2009.
What is the principal executive office address for PDS Biotechnology Corporation?
The principal executive offices are located at 303A College Road East, Princeton, NJ 08540.
Filing Stats: 467 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-03-13 06:02:05
Key Financial Figures
- $0.00033 — ich registered Common Stock, par value $0.00033 per share PDSB The Nasdaq Stock Mar
Filing Documents
- ef20023955_8k.htm (8-K) — 27KB
- ef20023955_ex99-1.htm (EX-99.1) — 21KB
- image00001.jpg (GRAPHIC) — 241KB
- 0001140361-24-012905.txt ( ) — 518KB
- pdsb-20240313.xsd (EX-101.SCH) — 4KB
- pdsb-20240313_lab.xml (EX-101.LAB) — 21KB
- pdsb-20240313_pre.xml (EX-101.PRE) — 16KB
- ef20023955_8k_htm.xml (XML) — 4KB
01
Item 8.01 Other Events. On March 13, 2024, PDS Biotechnology Corporation (the "Company") issued a press release announcing the publication of preclinical research and the issuance of a patent by the United States Patent and Trademark Office (USPTO) strengthening the foundation of the Company's infectious disease vaccine platform Infectimune . The Company is filing a copy of the press release, which is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release dated March 13, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PDS BIOTECHNOLOGY CORPORATION Date: March 13, 2024 By: /s/ Frank Bedu-Addo, Ph.D . Name: Frank Bedu-Addo, Ph.D. Title: President and Chief Executive Officer